Physician profile
Richard Jeffrey Handler
NPI 1932158235
$2,793.51
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $317 · 2021: $577 · 2022: $766 · 2023: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $447.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $495.95 | 2019-2023 | |
| Amgen INC. | $239.15 | 2019-2023 | Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $210.38 | 2019-2023 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $210.04 | 2021-2023 | |
| Vifor Pharma, INC. | $145.59 | 2019-2023 | Veltassa, Korsuva |
| Novartis Pharmaceuticals Corporation | $143.25 | 2019-2020 | |
| Medtronic, INC. | $124.99 | 2021 | |
| Horizon Therapeutics Plc | $121.22 | 2020-2023 | Krystexxa |
| Novo Nordisk INC | $118.62 | 2019-2023 | Ozempic |
| Opko Pharmaceuticals, LLC | $114.55 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $99.38 | 2021-2023 | Oxlumo |
| Resmed Corp | $75.79 | 2023 | |
| Mallinckrodt Enterprises LLC | $71.70 | 2019 | |
| Lilly USA, LLC | $71.57 | 2022-2023 | Mounjaro |
| Calliditas Therapeutics US INC. | $70.05 | 2022-2023 | Tarpeyo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $64.47 | 2022-2023 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $56.69 | 2019-2023 | Velphoro, Korsuva |
| Amicus Therapeutics, INC. | $46.32 | 2020-2021 | |
| Baxter Healthcare | $44.45 | 2020 | |
| Mallinckrodt Hospital Products INC. | $42.80 | 2022 | |
| Glaxosmithkline, LLC. | $39.13 | 2022-2023 | Benlysta |
| Genzyme Corporation | $38.23 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $29.75 | 2019 | |
| Akebia Therapeutics INC | $29.01 | 2019-2020 | |
| Daiichi Sankyo INC. | $25.12 | 2019 | |
| Shire North American Group INC | $22.93 | 2019 | |
| Aurinia Pharma U.S., INC. | $21.53 | 2022 | |
| Genentech USA, INC. | $20.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Handler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.